

Attorney Docket No. 9286.7
Application Serial No.: 10/019,902
Filed: July 2, 2002
Page 2 of 20

RECEIVED
CENTRAL FAX CENTER

JAN 05 2007

IN THE CLAIMS

Please amend the claims as follows. The following listing of claims replaces all prior versions.

1. (currently amended) A compound of the general formula (I)



wherein

X is an m-valent unit and

B are identical or different and denote K-R, wherein

K is a bond or is $A^1-(A^2-A^3)_k-sp$, wherein

A^1 is $(CH_2)_tY(CH_2)_u$, wherein

Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

(A^2-A^3) can be any A^2 and any A^3 in any combination,

A^2 is $-NHCO-$ or $-CONH-$,

A^3 is $(CH_2)_r$, $O(CH_2)_r$, or $S(CH_2)_r$, wherein

r = 1,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

R is hydrogen, sialic acid, sialyl lactose, sialyl lactosamine, lactose, mannose, $Gal\alpha 1-3Gal$, $Gal\alpha 1-3(Fuc\alpha 1-2)Gal$, $GalNAc\alpha 1-3(Fuc\alpha 1-2)Gal$, $Neu5Ac\alpha 2-6GalNAc$, $SiaLe^A$, $SiaLe^X$, HSO_3Le^A , HSO_3Le^X , $Gal\alpha 1-3Gal\beta 1-4GlcNAc$, $Gal\alpha 1-3Gal\beta 1-4Glc$, $Neu5Ac\alpha 2-6Gal\beta 1-4GlcNAc$, $HSO_3GlcA\beta 1-3Gal\beta 1-4Glc$, $HSO_3GlcA\beta 1-3Gal$, $HSO_3GlcA\beta 1-3Gal\beta 1-4GlcNAc\beta 1-3Gal\beta 1-4Glc$, $GalNAc\alpha 1-3(Fuc\alpha 1-2)Gal\beta 1-4GlcNAc$, $Gal\alpha 1-3(Fuc\alpha 1-2)Gal\beta 1-4GlcNAc$, $HSO_3(Sia)Le^X$, $HSO_3(Sia)Le^A$, Le^Y , $GlcNAc\beta 1-6(GlcNAc\beta 1-3)Gal\beta 1-4Glc$, $GalNAc\beta 1-4(Neu5Ac\alpha 2-3)Gal\beta 1-4Glc$, mannose-6-phosphate, $GalNAc\beta 1-4Glc$,

Attorney Docket No. 9286.7
Application Serial No.: 10/019,902
Filed: July 2, 2002
Page 3 of 20

4GlcNAc, oligo-sialic acid, N-glycolylneuraminic acid, Gal α 1-4Gal β 1-4Glc, or
Gal α 1-4Gal β 1-4GlcNAc; and

m is at least 23 or 4,

with the proviso that

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment X(K)_m is less than 20,000.

2. (previously presented) A compound according to claim 1, wherein the molar mass of the fragment X(K)_m is less than 4,000.

3. (currently amended) A compound according to claim 1, wherein

m is an integer from 2 to 3 or 4, and

X is CH_{4-m}, NH_{3-m}, N⁺H_{4-m}, >P-(when m = 3), >P⁺<(when m = 4), >B-(when m = 3), a linear atom group C₂H_{6-m}, >CH(CH₂)_zCH<, >C=C<, >N<, >N(CH₂)_zN< wherein z = 2 - 6, when m = 4), a carbocyclic atom group C₆H_{6-m}, C₆H_{12-m}, or a heterocyclic atom group C₃N₃ (when m = 3), C₄N₂ (when m = 4).

4. (previously presented) A compound according to claim 1, wherein there are at least 3 K.

5. (previously presented) A compound according to claim 1, wherein at least two R are not hydrogen.

6. (currently amended) A compound according to claim 1, wherein at least three R are not hydrogen. A compound of the general formula (I)

Attorney Docket No. 9286.7
Application Serial No.: 10/019,902
Filed: July 2, 2002
Page 4 of 20

X(B)_m (I)

wherein

X is an m-valent unit and

B are identical or different and denote K-R, wherein

K is a bond or is A¹-(A²-A³)_k-sp, wherein

A¹ is (CH₂)_tY(CH₂)_u, wherein

Y is >C=O, >NH, -O-, -S- or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

(A²-A³) can be any A² and any A³ in any combination.

A² is -NHCO- or -CONH-,

A³ is (CH₂)_r, O(CH₂)_r, or S(CH₂)_r, wherein

r = 1,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

R is hydrogen, sialic acid, sialyl lactose, sialyl lactosamine, lactose, mannose, Gal α 1-3Gal, Gal α 1-3(Fuc α 1-2)Gal, GalNAc α 1-3(Fuc α 1-2)Gal, Neu5Ac α 2-6GalNAc, SiaLe^A, SiaLe^X, HSO₃Le^A, HSO₃Le^X, Gal α 1-3Gal β 1-4GlcNAc, Gal α 1-3Gal β 1-4Glc, Neu5Ac α 2-6Gal β 1-4GlcNAc, HSO₃GlcA β 1-3Gal β 1-4GlcNAc, N-acetyl-lactosamine or poly-lactosamine, sialic acid benzyl glycoside, HSO₃GlcA β 1-3Gal, HSO₃GlcA β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc, GalNAc α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, Gal α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, HSO₃(Sia)Le^X, HSO₃(Sia)Le^A, Le^Y, GlcNAc β 1-6(GlcNAc β 1-3)Gal β 1-4Glc, GalNAc β 1-4(Neu5Ac α 2-3)Gal β 1-4Glc, mannose-6-phosphate, GalNAc β 1-4GlcNAc, oligo-sialic acid, N-glycolylneuraminic acid, Gal α 1-4Gal β 1-4Glc, or Gal α 1-4Gal β 1-4GlcNAc; and

m is at least 2,

with the proviso that

- (1) in the compound at least three R are not hydrogen,
- (2) there are at least two K that are not a bond, and

Attorney Docket No. 9286.7
Application Serial No.: 10/019,902
Filed: July 2, 2002
Page 5 of 20

- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
(4) the molar mass of the fragment X(K)_m is less than 20,000.

7-8. (canceled).

9. (currently amended) A compound according to claim 1, wherein
m is an integer from 2 to 4,

X is CH_{4-m},

A¹ is CH₂,

A² is NHCO,

A³ is CH₂,

k is 8,

sp is (CH₂)₃CONHCH₂CONHC₆H₄-4-CH₂O and

R is Neu5Aca2'6GalB1'4GlcNAc

A compound of the general formula (I)

X(B)_m (I)

wherein

X is CH_{4-m} and

B are identical or different and denote K-R, wherein

K is a bond or is A¹-(A²-A³)_t-sp, wherein

A¹ is CH₂, wherein

Y is >C=O, >NH, -O-, -S- or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

(A²-A³) can be any A² and any A³ in any combination.

A² is NHCO,

A³ is CH₂, wherein

r = 1.

Attorney Docket No. 9286.7
 Application Serial No.: 10/019,902
 Filed: July 2, 2002
 Page 6 of 20

sp is $(\text{CH}_2)_3\text{CONHCH}_2\text{CONHC}_6\text{H}_4\text{-4-CH}_2\text{O-}$, and

k is 8, and

R is Neu5Aca2-6Gal β 1-4GlcNAc; and

m is an integer from 2 to 4,

with the proviso that

- (1) in the compound at least one R is not hydrogen.
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment X(K)_m is less than 20,000.

10. (currently amended) An aggregate of the general formula (II):

$\{\text{X}(\text{B})_m\}_n$ (II)

wherein X(B)_m may be identical or different and denote a compound of the general formula (I),

X(B)_m (I)

wherein

X is an m-valent unit and

B are identical or different and denote K-R, wherein

K is a bond or is $A^1-(A^2-A^3)_k-sp$, wherein

A^1 is $(\text{CH}_2)_t\text{Y}(\text{CH}_2)_u$, wherein

Y is $>\text{C=O}$, $>\text{NH}$, $-\text{O}-$, $-\text{S}-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

(A^2-A^3) can be any A^2 and any A^3 in any combination,

A^2 is $-\text{NHCO-}$ or $-\text{CONH-}$,

A^3 is $(\text{CH}_2)_r\text{O}(\text{CH}_2)_s$, or $\text{S}(\text{CH}_2)_r$, wherein

r = 1,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

Attorney Docket No. 9286.7
Application Serial No.: 10/019,902
Filed: July 2, 2002
Page 7 of 20

R is hydrogen, sialic acid, sialyl lactose, sialyl lactosamine, lactose, mannose, Gal α 1-3Gal, Gal α 1-3(Fuc α 1-2)Gal, GalNAc α 1-3(Fuc α 1-2)Gal, Neu5Aca2-6GalNAc, SiaLe A , SiaLe X , HSO₃Le A , HSO₃Le X , Gal α 1-3Gal β 1-4GlcNAc, Gal α 1-3Gal β 1-4Glc, Neu5Aca2-6Gal β 1-4GlcNAc, HSO₃GlcA β 1-3Gal β 1-4GlcNAc, N-acetyl-lactosamine or polylactosamine, sialic acid benzyl glycoside, HSO₃GlcA β 1-3Gal, HSO₃GlcA β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc, GalNAc α , GalNAc α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, Gal α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, HSO₃(Sia)Le X , HSO₃(Sia)Le A , Le Y , GlcNAc β 1-6(GlcNAc β 1-3)Gal β 1-4Glc, GalNAc β 1-4(Neu5Aca2-3)Gal β 1-4Glc, mannose-6-phosphate, GalNAc β 1-4GlcNAc, oligo-sialic acid, N-glycolylneuraminic acid, Gal α 1-4Gal β 1-4Glc, or Gal α 1-4Gal β 1-4GlcNAc; and

m is at least 23 or 4,

with the proviso that

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment X(K)_m is less than 20,000, and
n is from 2 to 100,000,

and wherein X(B)_m are non-covalently bonded.

11. (previously presented) An aggregate according to claim 10 having a leaf-like, linear, cyclic, polycyclic, polyhedral, spherical or dendritic structure.

12. (currently amended) An aggregate according to claim 10 of two or more different compounds comprising a compound of the general formula (I)

X(B)_m (I)

wherein

X is an m-valent unit and

B are identical or different and denote K-R, wherein

Attorney Docket No. 9286.7
Application Serial No.: 10/019,902
Filed: July 2, 2002
Page 8 of 20

K is a bond or is $A^1-(A^2-A^3)_k-sp$, wherein
 A^1 is $(CH_2)_tY(CH_2)_u$, wherein
Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,
t is an integer from 0 to 6 and
u is an integer from 0 to 6,
 (A^2-A^3) can be any A^2 and any A^3 in any combination,
 A^2 is $-NHCO-$ or $-CONH-$,
 A^3 is $(CH_2)_r$, $O(CH_2)_r$, or $S(CH_2)_r$, wherein
r = 1,
sp is a divalent spacer or a bond, and
k is an integer from 5 to 100, and

R is hydrogen, sialic acid, sialyl lactose, sialyl lactosamine, lactose, mannose, Gal α 1-3Gal, Gal α 1-3(Fuc α 1-2)Gal, GalNAc α 1-3(Fuc α 1-2)Gal, Neu5Aca2-6GalNAc, SiaLe^A, SiaLe^X, HSO₃Le^A, HSO₃Le^X, Gal α 1-3Gal β 1-4GlcNAc, Gal α 1-3Gal β 1-4Glc, Neu5Aca2-6Gal β 1-4GlcNAc, HSO₃GlcA β 1-3Gal β 1-4GlcNAc, N-acetyl-lactosamine or polylactosamine, sialic acid benzyl glycoside, HSO₃GlcA β 1-3Gal, HSO₃GlcA β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc, GalNAca, GalNAc α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, Gal α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, HSO₃(Sia)Le^X, HSO₃(Sia)Le^A, Le^Y, GlcNAc β 1-6(GlcNAc β 1-3)Gal β 1-4Glc, GalNAc β 1-4(Neu5Aca2-3)Gal β 1-4Glc, mannose-6-phosphate, GalNAc β 1-4GlcNAc, oligo-sialic acid, N-glycolylneuraminic acid, Gal α 1-4Gal β 1-4Glc, or Gal α 1-4Gal β 1-4GlcNAc; and
m is at least 23 or 4,

with the proviso that

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment X(K)_m is less than 20,000.

Attorney Docket No. 9286.7
Application Serial No.: 10/019,902
Filed: July 2, 2002
Page 9 of 20

13. (canceled)

14. (previously presented) A method according to claim 27, further comprising adding a concentrated salt solution, changing the pH or the temperature, or adding organic solvents.

15. (currently amended) A method for changing the structure of an aggregate of the general formula (II)

$\{X(B)_m\}_n$ (II)

wherein $X(B)_m$ may be identical or different and denote a compound of the general formula (I),

$X(B)_m$ (I)

wherein

X is an m-valent unit and

B are identical or different and denote K-R, wherein

K is a bond or is $A^1-(A^2-A^3)_k-sp$, wherein

A^1 is $(CH_2)_tY(CH_2)_u$, wherein

Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

(A^2-A^3) can be any A^2 and any A^3 in any combination,

A^2 is $-NHCO-$ or $-CONH-$,

A^3 is $(CH_2)_r$, $O(CH_2)_r$, or $S(CH_2)_r$, wherein

r = 1,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

R is hydrogen, sialic acid, sialyl lactose, sialyl lactosamine, lactose, mannose, $Gal\alpha 1-3Gal$, $Gal\alpha 1-3(Fuc\alpha 1-2)Gal$, $GalNAc\alpha 1-3(Fuc\alpha 1-2)Gal$, $Neu5Ac\alpha 2-6GalNAc$, $SiaLe^A$, $SiaLe^X$, HSO_3Le^A , HSO_3Le^X , $Gal\alpha 1-3Gal\beta 1-4GlcNAc$, $Gal\alpha 1-3Gal\beta 1-4Glc$, $Neu5Ac\alpha 2-6Gal\beta 1-4GlcNAc$, $HSO_3GlcA\beta 1-3Gal\beta 1-4GlcNAc$, N-acetyl-lactosamine or polylactosamine, sialic acid benzyl glycoside, $HSO_3GlcA\beta 1-3Gal$,

Attorney Docket No. 9286.7
Application Serial No.: 10/019,902
Filed: July 2, 2002
Page 10 of 20

$\text{HSO}_3\text{GlcA}\beta 1\text{-}3\text{Gal}\beta 1\text{-}4\text{GlcNAc}\beta 1\text{-}3\text{Gal}\beta 1\text{-}4\text{Glc}$, $\text{GalNAc}\alpha$, $\text{GalNAc}\alpha 1\text{-}3(\text{Fuc}\alpha 1\text{-}2)\text{Gal}\beta 1\text{-}4\text{GlcNAc}$, $\text{Gal}\alpha 1\text{-}3(\text{Fuc}\alpha 1\text{-}2)\text{Gal}\beta 1\text{-}4\text{GlcNAc}$, $\text{HSO}_3(\text{Sia})\text{Le}^X$, $\text{HSO}_3(\text{Sia})\text{Le}^A$, Le^Y , $\text{GlcNAc}\beta 1\text{-}6(\text{GlcNAc}\beta 1\text{-}3)\text{Gal}\beta 1\text{-}4\text{Glc}$, $\text{GalNAc}\beta 1\text{-}4(\text{Neu5Ac}\alpha 2\text{-}3)\text{Gal}\beta 1\text{-}4\text{Glc}$, mannose-6-phosphate, $\text{GalNAc}\beta 1\text{-}4\text{GlcNAc}$, oligo-sialic acid, N-glycolylneuraminic acid, $\text{Gal}\alpha 1\text{-}4\text{Gal}\beta 1\text{-}4\text{Glc}$, or $\text{Gal}\alpha 1\text{-}4\text{Gal}\beta 1\text{-}4\text{GlcNAc}$; and

m is at least 23 or 4,

with the proviso that

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment X(K)_m is less than 20,000, and

n is from 2 to 100,000,

and wherein X(B)_m are non-covalently bonded,
further comprising adding a concentrated salt solution, changing the temperature or the pH and/or adding urea, trifluoroethanol or peptides.

16. (previously presented) A method according to claim 27 further comprising increasing the specific physiological activities of molecules by incorporating a radical R into a compound of the general formula (I).

17. (canceled)

18. (currently amended) A method of treating diseases arising from inflammation, viral and bacterial infections, influenza viruses, selectin-mediated inflammatory processes, tumour metastases, or in the neutralisation of antibodies in autoimmune disorders and transplants; said method comprising administering a compound of the general formula (I)

$X(B)_m$ (I)

wherein

Attorney Docket No. 9286.7
Application Serial No.: 10/019,902
Filed: July 2, 2002
Page 11 of 20

- X is an m-valent unit and
- B are identical or different and denote K-R, wherein
- K is a bond or is A¹-(A²-A³)_k-sp, wherein
- A¹ is (CH₂)_tY(CH₂)_u, wherein
- Y is >C=O, >NH, -O-, -S- or a bond,
- t is an integer from 0 to 6 and
- u is an integer from 0 to 6,
- (A²-A³) can be any A² and any A³ in any combination,
- A² is -NHCO- or -CONH-,
- A³ is (CH₂)_r, O(CH₂)_r, or S(CH₂)_r, wherein
- r = 1,
- sp is a divalent spacer or a bond, and
- k is an integer from 5 to 100, and
- R is hydrogen, sialic acid, sialyl lactose, sialyl lactosamine, lactose, mannose, Gal α 1-3Gal, Gal α 1-3(Fuc α 1-2)Gal, GalNAc α 1-3(Fuc α 1-2)Gal, Neu5Ac α 2-6GalNAc, SiaLe^A, SiaLe^X, HSO₃Le^A, HSO₃Le^X, Gal α 1-3Gal β 1-4GlcNAc, Gal α 1-3Gal β 1-4Glc, Neu5Ac α 2-6Gal β 1-4GlcNAc, HSO₃GlcA β 1-3Gal β 1-4GlcNAc, N-acetyl-lactosamine or polylactosamine, sialic acid benzyl glycoside, HSO₃GlcA β 1-3Gal, HSO₃GlcA β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc, GalNAc α , GalNAc α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, Gal α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, HSO₃(Sia)Le^X, HSO₃(Sia)Le^A, Le^Y, GlcNAc β 1-6(GlcNAc β 1-3)Gal β 1-4Glc, GalNAc β 1-4(Neu5Ac α 2-3)Gal β 1-4Glc, mannose-6-phosphate, GalNAc β 1-4GlcNAc, oligo-sialic acid, N-glycolylneuraminic acid, Gal α 1-4Gal β 1-4Glc, or Gal α 1-4Gal β 1-4GlcNAc; and
- m is at least 23 or 4,
- with the proviso that
- (1) in the compound at least one R is not hydrogen,
 - (2) there are at least two K that are not a bond, and
 - (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and

Attorney Docket No. 9286.7
Application Serial No.: 10/019,902
Filed: July 2, 2002
Page 12 of 20

- (4) the molar mass of the fragment X(K)_m is less than 20,000; or
administering into an aggregate of the general formula (II)

{X(B)_m}_n (II)

wherein

X(B)_m may be identical or different and denote a compound of the general formula (I), and
n is from 2 to 100,000,
and wherein X(B)_m are non-covalently bonded.

19. (canceled)

20. (previously presented) A method according to claim 18 further comprising
preparing functionalized molecular surfaces.

21-22. (canceled).

23. (currently amended) A compound of the general formula (I),

X(B)_m (I)

wherein

X is an m-valent unit and

B are identical or different and denote K-R, wherein

K is a bond or is A¹-(A²-A³)_k-sp, wherein

A¹ is (CH₂)_tY(CH₂)_u, wherein

Y is >C=O, >NH, -O-, -S- or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

(A²-A³) can be any A² and any A³ in any combination,

A² is -NHCO- or -CONH-,

A³ is (CH₂)_r, O(CH₂)_s, or S(CH₂)_r, wherein

r = 1,

sp is a divalent spacer or a bond, and

Attorney Docket No. 9286.7
Application Serial No.: 10/019,902
Filed: July 2, 2002
Page 13 of 20

k is an integer from 5 to 100, and

R is hydrogen, sialic acid, sialyl lactose, sialyl lactosamine, lactose, mannose, Gal α 1-3Gal, Gal α 1-3(Fuc α 1-2)Gal, GalNAc α 1-3(Fuc α 1-2)Gal, Neu5Aca2-6GalNAc, SiaLe^A, SiaLe^X, HSO₃Le^A, HSO₃Le^X, Gal α 1-3Gal β 1-4GlcNAc, Gal α 1-3Gal β 1-4Glc, Neu5Aca2-6Gal β 1-4GlcNAc, HSO₃GlcA β 1-3Gal β 1-4GlcNAc, N-acetyl-lactosamine or polylactosamine, sialic acid benzyl glycoside, HSO₃GlcA β 1-3Gal, HSO₃GlcA β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc, GalNAc α , GalNAc α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, Gal α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, HSO₃(Sia)Le^X, HSO₃(Sia)Le^A, Le^Y, GlcNAc β 1-6(GlcNAc β 1-3)Gal β 1-4Glc, GalNAc β 1-4(Neu5Aca2-3)Gal β 1-4Glc, mannose-6-phosphate, GalNAc β 1-4GlcNAc, oligo-sialic acid, N-glycolylneuraminic acid, Gal α 1-4Gal β 1-4Glc, or Gal α 1-4Gal β 1-4GlcNAc; and

m is at least 23 or 4,

with the proviso that

- (1) X, B and m are so selected that an intermolecular association of the K in liquid phase is possible, especially under aqueous conditions, by the formation of hydrogen bonds, with formation of aggregates, and
- (2) the molar mass of the fragment X(K)_m is less than 20,000, especially less than 4000.


24-26. (canceled)

27. (currently amended) A method of preparing an aggregate comprising: preparing a compound of the general formula (II)



wherein

X(B)_m may be identical or different and denote a compound of the general formula (I),



wherein

X is an m-valent unit and

B are identical or different and denote K-R, wherein

K is a bond or is A¹-(A²-A³)_k-sp, wherein

Attorney Docket No. 9286.7
Application Serial No.: 10/019,902
Filed: July 2, 2002
Page 14 of 20

A^1 is $(CH_2)_t Y(CH_2)_u$, wherein
 Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,
 t is an integer from 0 to 6 and
 u is an integer from 0 to 6,

(A^2-A^3) can be any A^2 and any A^3 in any combination,

A^2 is $-NHCO-$ or $-CONH-$,

A^3 is $(CH_2)_r O(CH_2)_s$, or $S(CH_2)_k$, wherein

$r = 1$,

s is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

R is hydrogen, sialic acid, sialyl lactose, sialyl lactosamine, lactose, mannose, $Gal\alpha 1-3Gal$, $Gal\alpha 1-3(Fuc\alpha 1-2)Gal$, $GalNAc\alpha 1-3(Fuc\alpha 1-2)Gal$, $Neu5Ac\alpha 2-6GalNAc$, $SiaLe^A$, $SiaLe^X$, HSO_3Le^A , HSO_3Le^X , $Gal\alpha 1-3Gal\beta 1-4GlcNAc$, $Gal\alpha 1-3Gal\beta 1-4Glc$, $Neu5Ac\alpha 2-6Gal\beta 1-4GlcNAc$, $HSO_3GlcA\beta 1-3Gal\beta 1-4GlcNAc$, N-acetyl-lactosamine or poly-lactosamine, sialic acid benzyl glycoside, $HSO_3GlcA\beta 1-3Gal$, $HSO_3GlcA\beta 1-3Gal\beta 1-4GlcNAc\beta 1-3Gal\beta 1-4Glc$, $GalNAc\alpha$, $GalNAc\alpha 1-3(Fuc\alpha 1-2)Gal\beta 1-4GlcNAc$, $Gal\alpha 1-3(Fuc\alpha 1-2)Gal\beta 1-4GlcNAc$, $HSO_3(Sia)Le^X$, $HSO_3(Sia)Le^A$, Le^Y , $GlcNAc\beta 1-6(GlcNAc\beta 1-3)Gal\beta 1-4Glc$, $GalNAc\beta 1-4(Neu5Ac\alpha 2-3)Gal\beta 1-4Glc$, mannose-6-phosphate, $GalNAc\beta 1-4GlcNAc$, oligo-sialic acid, N-glycolylneuraminic acid, $Gal\alpha 1-4Gal\beta 1-4Glc$, or $Gal\alpha 1-4Gal\beta 1-4GlcNAc$; and

m is at least 23 or 4,

with the proviso that

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X , B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment $X(K)_m$ is less than 20,000, and

n is from 2 to 100,000,

and wherein $X(B)_n$ are non-covalently bonded.

Attorney Docket No. 9286.7
Application Serial No.: 10/019,902
Filed: July 2, 2002
Page 15 of 20

28. (currently amended) A method of preparing a therapeutic drug comprising:
preparing the compound of the general formula (I)

$X(B)_m$ (I)

wherein

X is an m-valent unit and

B are identical or different and denote K-R, wherein

K is a bond or is $A^1-(A^2-A^3)_k-sp$, wherein

A^1 is $(CH_2)_tY(CH_2)_u$, wherein

Y is $>C=O$, $>NH$, $-O-$, $-S-$ or a bond,

t is an integer from 0 to 6 and

u is an integer from 0 to 6,

(A^2-A^3) can be any A^2 and any A^3 in any combination,

A^2 is $-NHCO-$ or $-CONH-$,

A^3 is $(CH_2)_r O(CH_2)_r$, or $S(CH_2)_r$, wherein

r = 1,

sp is a divalent spacer or a bond, and

k is an integer from 5 to 100, and

R is hydrogen, sialic acid, sialyl lactose, sialyl lactosamine, lactose, mannose, Gal α 1-3Gal, Gal α 1-3(Fuc α 1-2)Gal, GalNAc α 1-3(Fuc α 1-2)Gal, Neu5Ac α 2-6GalNAc, SiaLe^A, SiaLe^X, HSO₃Le^A, HSO₃Le^X, Gal α 1-3Gal β 1-4GlcNAc, Gal α 1-3Gal β 1-4Glc, Neu5Ac α 2-6Gal β 1-4GlcNAc, HSO₃GlcA β 1-3Gal β 1-4GlcNAc, N-acetyl-lactosamine or polylactosamine, sialic acid benzyl glycoside, HSO₃GlcA β 1-3Gal, HSO₃GlcA β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc, GalNAc α , GalNAc α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, Gal α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc, HSO₃(Sia)Le^X, HSO₃(Sia)Le^A, Le^Y, GlcNAc β 1-6(GlcNAc β 1-3)Gal β 1-4Glc, GalNAc β 1-4(Neu5Ac α 2-3)Gal β 1-4Glc, mannose-6-phosphate, GalNAc β 1-4GlcNAc, oligo-sialic acid, N-glycolylneuraminic acid, Gal α 1-4Gal β 1-4Glc, or Gal α 1-4Gal β 1-4GlcNAc; and


m is at least 23 or 4,

with the proviso that

Attorney Docket No. 9286.7
Application Serial No.: 10/019,902
Filed: July 2, 2002
Page 16 of 20

- (1) in the compound at least one R is not hydrogen,
- (2) there are at least two K that are not a bond, and
- (3) X, B and m are so selected that an intermolecular association of the K in liquid phase by the formation of hydrogen bonds is possible, with formation of aggregates that present on the surface a plurality of R that are not hydrogen, and
- (4) the molar mass of the fragment $X(K)_m$ is less than 20,000; or

preparing the compound of the general formula (II):



wherein

$X(B)_m$ may be identical or different and denote a compound of the general formula (I), and n is from 2 to 100,000,
and wherein $X(B)_m$ are non-covalently bonded; and
a pharmaceutically acceptable carrier.

29. (canceled)